Spring Works Therapeutics, Inc. SWTX
We take great care to ensure that the data presented and summarized in this overview for SpringWorks Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SWTX
View all-
Vanguard Group Inc Valley Forge, PA7.16MShares$357 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$280 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.46MShares$172 Million5.51% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.27MShares$163 Million0.01% of portfolio
-
State Street Corp Boston, MA3MShares$150 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx2.89MShares$144 Million2.02% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.39MShares$119 Million0.1% of portfolio
-
Capital International Investors Los Angeles, CA2.36MShares$118 Million0.02% of portfolio
-
Morgan Stanley New York, NY2MShares$99.5 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.67MShares$83.2 Million0.0% of portfolio
Latest Institutional Activity in SWTX
Top Purchases
Top Sells
About SWTX
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Insider Transactions at SWTX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 03
2025
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
49,000
-0.99%
|
$2,695,000
$55.08 P/Share
|
Mar 03
2025
|
Badreddin Edris Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.72%
|
$1,080,000
$54.67 P/Share
|
Feb 27
2025
|
Saqib Islam Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
30,756
-2.97%
|
$1,630,068
$53.41 P/Share
|
Feb 20
2025
|
Daniel Lynch Director |
SELL
Open market or private sale
|
Direct |
47,600
-18.93%
|
$2,856,000
$60.69 P/Share
|
Feb 20
2025
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,016
-1.61%
|
$61,976
$61.19 P/Share
|
Feb 20
2025
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,328
-1.38%
|
$1,759,680
$60.67 P/Share
|
Feb 14
2025
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,672
-0.99%
|
$629,648
$59.92 P/Share
|
Feb 14
2025
|
Daniel Lynch Director |
SELL
Open market or private sale
|
Direct |
400
-0.31%
|
$24,000
$60.0 P/Share
|
Feb 12
2025
|
Saqib Islam Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,186
-1.21%
|
$777,974
$59.28 P/Share
|
Feb 12
2025
|
Saqib Islam Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,309
+7.27%
|
-
|
Feb 10
2025
|
Daniel Pichl Chief People Officer |
SELL
Open market or private sale
|
Direct |
29,750
-14.23%
|
$1,606,500
$54.81 P/Share
|
Feb 10
2025
|
Daniel Pichl Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,750
+17.07%
|
$803,250
$27.64 P/Share
|
Feb 10
2025
|
Badreddin Edris Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
30,000
-13.65%
|
$1,590,000
$53.13 P/Share
|
Feb 10
2025
|
Julie Hambleton Director |
SELL
Open market or private sale
|
Direct |
13,774
-77.08%
|
$730,022
$53.01 P/Share
|
Feb 10
2025
|
Julie Hambleton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,774
+43.53%
|
$440,768
$32.27 P/Share
|
Feb 10
2025
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
48,000
-4.57%
|
$2,544,000
$53.3 P/Share
|
Feb 10
2025
|
Daniel Lynch Director |
SELL
Open market or private sale
|
Direct |
175,000
-24.32%
|
$9,450,000
$54.54 P/Share
|
Jan 10
2025
|
Tai An Lin Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,929
+17.34%
|
-
|
Jan 10
2025
|
Michael Nofi Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,929
+18.45%
|
-
|
Jan 10
2025
|
Perier I Francis Jr Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,779
+16.21%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 303K shares |
---|---|
Exercise of conversion of derivative security | 43.5K shares |
Open market or private sale | 666K shares |
---|---|
Payment of exercise price or tax liability | 159K shares |